NVRO Overview

Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.

Wall Street analysts forecast NVRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVRO is5.85 USD with a low forecast of 5.85 USD and a high forecast of 5.85 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Nevro Corp revenue for the last quarter amounts to 96.91M USD, decreased -6.69

Nevro Corp. EPS for the last quarter amounts to -0.41 USD, decreased -36.92

Nevro Corp (NVRO) has 1215 emplpoyees as of February 16 2026.

Today NVRO has the market capitalization of 0.00 USD.